Current thinking on chronic renal allograft rejection: Issues, concerns, and recommendations from a 1997 roundtable discussion

被引:113
作者
Monaco, AP
Burke, JF
Ferguson, RM
Halloran, PF
Kahan, BD
Light, JA
Matas, AJ
Solez, K
机构
[1] Harvard Univ, New England Deaconess Hosp, Sch Med, Boston, MA 02215 USA
[2] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA
[3] Ohio State Univ, Columbus, OH 43210 USA
[4] Univ Alberta, Edmonton, AB, Canada
[5] Univ Texas, Hlth Sci Ctr, Houston, TX USA
[6] Washington Hosp Ctr, Univ Hlth Sci, Washington, DC 20010 USA
[7] Univ Minnesota, Edina, MN USA
关键词
chronic rejection; renal transplant; renal biopsy; immunosuppression; compliance; cyclosporine; nephron mass; serum creatinine;
D O I
10.1016/S0272-6386(99)70273-8
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Chronic rejection accounts for most renal allograft losses after the first year posttransplantation. On March 24 and 25, 1997, a roundtable of five transplant surgeons, two nephrologists, and one pathologist assembled in Dallas, Texas, to review critical issues surrounding chronic renal allograft rejection. This article summarizes the presentations and relevant discussions of this meeting regarding the cause of chronic rejection, clinical diagnoses, risk factors, future prospects for intervention strategies, and general recommendations for the transplant community. Growing evidence indicates that chronic rejection is the aggregate sum of irreversible immunologic and nonimmunologic injuries to the renal graft over time. A history of acute rejection episodes and inadequate immunosuppression, likely attributable to inconsistent cyclosporine exposure or poor patient compliance, are among the most recognizable immunologic risk factors for chronic rejection. Donor organ quality, delayed graft function, and other donor and recipient variables leading to reduced nephron mass are nonimmunologic factors that contribute to the progressive deterioration of renal graft function. Clinical management of renal transplant recipients should incorporate both immunologic- and nonimmunologic-based intervention strategies aimed at minimizing risk factors to thwart the progression of chronic rejection and improve long-term allograft and patient survival. (C) 1999 by the National Kidney Foundation, Inc.
引用
收藏
页码:150 / 160
页数:11
相关论文
共 47 条
[1]  
ALMOND PS, 1993, TRANSPLANT P, V25, P936
[2]   RISK-FACTORS FOR CHRONIC REJECTION IN RENAL-ALLOGRAFT RECIPIENTS [J].
ALMOND, PS ;
MATAS, A ;
GILLINGHAM, K ;
DUNN, DL ;
PAYNE, WD ;
GORES, P ;
GRUESSNER, R ;
NAJARIAN, JS ;
FERGUSON ;
PAUL ;
SCHAFFER .
TRANSPLANTATION, 1993, 55 (04) :752-757
[3]   EARLY VERSUS LATE ACUTE RENAL-ALLOGRAFT REJECTION - IMPACT ON CHRONIC REJECTION [J].
BASADONNA, GP ;
MATAS, AJ ;
GILLINGHAM, KJ ;
PAYNE, WD ;
DUNN, DL ;
SUTHERLAND, DER ;
GORES, PF ;
GRUESSNER, RWG ;
NAJARIAN, JS .
TRANSPLANTATION, 1993, 55 (05) :993-995
[4]   Quantitating immunosuppression - Estimating the 50% inhibitory concentration for in vivo cyclosporine in mice [J].
Batiuk, TD ;
Urmson, J ;
Vincent, D ;
Yatscoff, RW ;
Halloran, PF .
TRANSPLANTATION, 1996, 61 (11) :1618-1624
[5]   The downstream consequences of calcineurin inhibition [J].
Batiuk, TD ;
Halloran, PF .
TRANSPLANTATION PROCEEDINGS, 1997, 29 (1-2) :1239-1240
[6]   CALCINEURIN ACTIVITY IS ONLY PARTIALLY INHIBITED IN LEUKOCYTES OF CYCLOSPORINE-TREATED PATIENTS [J].
BATIUK, TD ;
PAZDERKA, F ;
HALLORAN, PF .
TRANSPLANTATION, 1995, 59 (10) :1400-1404
[7]   CYCLOSPORINE INHIBITION OF CALCINEURIN ACTIVITY IN HUMAN-LEUKOCYTES IN-VIVO IS RAPIDLY REVERSIBLE [J].
BATIUK, TD ;
PAZDERKA, F ;
ENNS, J ;
DECASTRO, L ;
HALLORAN, PF .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (03) :1254-1260
[8]  
BRENNER BM, 1992, J AM SOC NEPHROL, V3, P162
[9]  
Cecka J M, 1997, Clin Transpl, P1
[10]   ANALYSES OF THE UNOS-SCIENTIFIC-RENAL-TRANSPLANT-REGISTRY AT 3 YEARS - EARLY EVENTS AFFECTING TRANSPLANT SUCCESS [J].
CECKA, JM ;
CHO, YW ;
TERASAKI, PI .
TRANSPLANTATION, 1992, 53 (01) :59-64